Cytovance Biologics hires vp of sales and business development

Valerie McDonnell joins from Althea

Cytovance Biologics, a biopharmaceutical contract manufacturing company specialising in the production of therapeutic proteins and antibodies from mammalian cell culture, has appointed Valerie McDonnell as vice president of sales and business development.

McDonnell has more than 22 years’ experience in the biotech industry. Prior to joining Cytovance she was vice president of sales at Althea.

Before joining Althea she was a study director at BioReliance where she was responsible for client programmes in the Molecular Biology Department. She also worked at The Institute for Genomic Research (TIGR) and participated in the Haemophilus influenzae sequencing programme.

You may also like

Manufacturing
Avantor and Cytovance collaborate on plasmid DNA supply

Avantor and Cytovance collaborate on plasmid DNA supply

The collaboration extends Avantor’s offering of critical materials for vaccines and therapeutics focused on cell and gene therapy
Manufacturing

Cytovance Biologics to expand microbial manufacturing

Has acquired 100L and 1,000L fermenters
Manufacturing

Cytovance Biologics to expand production capabilities in 2013

Installs a 1,000L SUB bioreactor, 5,000L stainless steel bioreactor and fill/finish line
Manufacturing

Cytovance adds 1,000L bioreactor to mammalian facility

Will complement existing manufacturing process trains in Oklahoma City
Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Design & Build
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Manufacturing
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility

The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Subscribe now